AskBio Completes Enrollment for Phase 2 Gene Therapy Trial Targeting Heart Failure
The GenePHIT study evaluating investigational therapy AB-1002 for heart failure with reduced ejection fraction has fully enrolled 173 patients, with initial results expected in early 2027.
Patient Enrollment For Clinical Trial | 02/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy